Kate Surdez

Human Resources Officer at MIMEDX GROUP, INC.

Health Technology

Producer Manufacturing

Consumer Services

Profile

Kate Surdez is currently the Chief Human Resources Officer at MiMedx Group, Inc. She previously worked as a Global Director at AstraZeneca PLC, Director-Human Resources at Frederick Manufacturing Corp., Senior Vice President & Head-Human Resources at Viela Bio, Inc., and Vice President-People at Vaxxinity, Inc. She obtained an undergraduate degree from The University of North Carolina at Wilmington.

Kate Surdez active positions

Companies	Position	Start
MIMEDX GROUP, INC.	Human Resources Officer	17/07/2022

All active positions of Kate Surdez

Former positions of Kate Surdez

Companies	Position	End
VAXXINITY, INC.	Human Resources Officer	-
ASTRAZENECA PLC	Corporate Officer/Principal	-
Frederick Manufacturing Corp.	Human Resources Officer	-
VIELA BIO, INC.	Human Resources Officer	-

See the detail of Kate Surdez's experience

Training of Kate Surdez

The University of North Carolina at Wilmington

Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Kate Surdez's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	3
ASTRAZENECA PLC	Health Technology
VAXXINITY, INC.	Health Technology
MIMEDX GROUP, INC.	Health Technology

Private companies	2
Frederick Manufacturing Corp.	Producer Manufacturing
Viela Bio, Inc. Viela Bio, Inc. BiotechnologyHealth Technology Viela Bio, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatment for autoimmune and inflammatory diseases. The firms product candidate includes inebilizumab, which is a humanized monoclonal antibody (mAb), designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells; VIB4920, which is a fusion protein designed to bind to CD40L on activated T cells, blocking their interaction with CD40-expressing B cells and potentially other binding partners; and VIB7734, which is a humanized mAb intended to be a novel treatment for autoimmune diseases where the pathology is driven principally by overproduction of type I interferons and other cytokines secreted by pDCs. The company was founded on December 11, 2017 and is headquartered in Gaithersburg, MD.	Health Technology

Private companies

Frederick Manufacturing Corp.

Producer Manufacturing